Bladder cancer treatments are hampered by high recurrence, requiring multiple therapeutic interventions which are highly invasive and cause side effects, underscoring the need for innovative treatments. In the pursuit of advancing bladder cancer treatment, immuno-oncology shows promise. This blog delves into the importance of identifying antigens in the development of targeted cancer therapies.  

Obesity is closely connected to autophagy, a vital cellular process impacting metabolic health. Targets which affect autophagy may therefore be a promising therapeutic approach.

Despite progress, there is no cure for AD, necessitating on-going research into biological targets to develop effective treatments. Using Causaly, MAPK14 was identified as a potential target associated with AD progression which has been studied in mice.    

Ubiquitination plays a key role in the pathophysiology of multiple myeloma, highlighting its promise as a therapeutic target for this plasma cell malignancy. In this blog, we used Causaly to explore genetic alterations affecting by ubiquitination in multiple myeloma.

Atopic eczema, the most common type of eczema, significantly impacts quality of life. Its complexity, influenced by genetic, environmental, and immunological factors, underscores the importance of target discovery for innovative treatments. Identifying novel targets may pave the way for more effective treatments that address the underlying causes of disease.

DMD is a fatal disease with no cure. Identifying biomarkers linked to DMD patient survival is vital for understanding disease progression, evaluating treatment effectiveness, and enhancing outcomes for those with this rare disease.

Neuroinflammation plays a key role in the pathogenesis of Parkinson’s Disease (PD). Understanding biological targets associated with neuroinflammation in this disease may pave the way for effective treatments.

Understanding GOF mutations is crucial for developing targeted therapies which inhibit the activity of aberrant proteins. Here, we explored FLT3 and NOTCH1 as GOF mutations associated with leukemia disease progression.

Poor validation of drug targets has been linked to costly clinical failures and low drug approval rates. Identifying promising therapeutic targets is therefore crucial in the management of complex diseases, such as Respiratory Distress Syndrome (RDS). In this use case, RAGE was identified as a potential target for RDS in adults.

Inflammatory Bowel Disease (IBD) affects millions of people worldwide. In Crohn’s disease, one of the main forms of IBD, biomarkers are pivotal for diagnosis and treatment guidance.

Spinocerebellar ataxia is a neurodegenerative disease, affecting 1 to 5 people per 100,000. The identification of biomarkers can provide key insights into the state and progression of a disease, in addition to patient response to treatments. As such, biomarkers can improve the success rates of drug development, accelerating the availability of new therapeutics.

Vector-borne diseases account for over 17% of all infectious diseases, posing a threat to over half the global population. However, the indiscriminate use of insecticides has led to the development of resistance in mosquitoes.

SERCA enzymes have emerged as potential therapeutic targets for Polycystic Kidney Disease (PKD), a prevalent hereditary kidney disease estimated to affect over 12 million people worldwide.

Atherosclerosis is one of the leading causes of death worldwide. Biomarkers play a crucial role in comprehending atherosclerosis, providing measurable indicators of disease presence, progression, and treatment response.

Pulmonary fibrosis is a disease where the lungs develop scarring, causing difficulty in breathing and reduced lung function. Oxidoreductases show promise as targets for pulmonary fibrosis due to their pivotal role in modulating oxidative stress and fibrosis.

In the evolving landscape of modern medicine, biomarkers are at the forefront of clinical research. Biomarkers can serve as objective measures of treatment response, guiding patients towards the most suitable therapies and reducing the risk of unnecessary and potentially harmful treatments.

miRNA therapeutics face numerous challenges including targeted delivery, specificity, stability, immune response, and toxicity. Overcoming these challenges is paramount for success.

Head and neck cancers account for nearly 4% of all cancers in the US. The most common type is oral cancer, estimated to cause over 170,000 global deaths in 2020 alone. These statistics highlight the urgent need for more research and better treatments.

Pharmacogenomics is an emerging field that combines pharmacology and genomics to identify genetic factors influencing individual responses to medications. This innovative approach opens doors to more effective and personalized therapies, promoting patient safety and providing tailored treatment options.

In the world of life sciences, we’re standing at the edge of a transformative era. The last decade has seen machine learning carve out significant advancements, enabling experts to predict protein interactions and design molecules with unprecedented precision.